For Institutions
About
Macquarie's Tony Ren maintained a Buy rating on BeiGene Ltd with a price target of HK$236.00. The shares closed at HK$192.00. Ren, who covers the Healthcare sector, has an average return of 12.6% and a 58.70% success rate. BeiGene Ltd has a Strong Buy consensus with a price target of HK$239.97.
Montage Technology Submits Application to Chinese Regulators for Hong Kong Listing
